Related Experiment Video
Updated: Jun 13, 2026
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
Proteomic analysis of human ovarian cancer paclitaxel-resistant cell lines
1Department of Gynecology and Obstetrics, Xiangya Hospital, Central South University, Changsha 410008, China. caolanqin@163.com
Objective:
To study the proteins related to paclitaxel-resistant of ovarian cancer cell line.
Methods:
The total proteins of paclitaxel-resistant and paclitaxel-sensitive human ovarian cancer cell lines were separated by 2-dimensional gel electrophoresis (2-DE). The differentially expressed proteins were analyzed using image analysis software. The differential proteins were identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Western blot was used to determine the differential expression levels of the 2 proteins.
Results:
Forty differentially expressed proteins were found by image analysis software, and 24 differential proteins were identified by mass spectrometry. These proteins included proliferation cell nuclear antigen (PCNA), nm23, prohibitin (PHB), annexin, alpha-enolase, heat shock protein (HSP), and so on.
Conclusion:
Twenty-four proteins in human ovarian cancer cell lines of paclitaxel-resistant and paclitaxel-sensitive are found by proteomic techniques, which may be involved in the paclitaxel-resistance of human ovarian cancer cells.
Insights
Researchers identified 24 proteins associated with paclitaxel resistance in ovarian cancer cells using proteomic techniques. These findings may offer new insights into overcoming drug resistance in ovarian cancer treatment.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Paclitaxel is a key chemotherapy drug for ovarian cancer.
- Acquired paclitaxel resistance remains a significant challenge in ovarian cancer treatment.
- Understanding the molecular mechanisms of resistance is crucial for developing effective therapies.
Purpose of the Study:
- To investigate protein expression differences between paclitaxel-resistant and sensitive human ovarian cancer cell lines.
- To identify specific proteins that may contribute to paclitaxel resistance.
- To explore potential therapeutic targets for overcoming drug resistance.
Main Methods:
- Utilized 2-dimensional gel electrophoresis (2-DE) to separate total proteins.
- Employed image analysis software for differential protein expression analysis.
- Identified differentially expressed proteins using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS).
- Validated protein expression levels with Western blot analysis.
Main Results:
- Identified 40 differentially expressed proteins via image analysis.
- Successfully identified 24 unique proteins using mass spectrometry.
- Key identified proteins include proliferation cell nuclear antigen (PCNA), nm23, prohibitin (PHB), annexin, alpha-enolase, and heat shock protein (HSP).
Conclusions:
- Proteomic analysis revealed 24 proteins differentially expressed in paclitaxel-resistant versus sensitive ovarian cancer cells.
- These identified proteins are potentially involved in the development of paclitaxel resistance.
- Further research into these proteins may lead to novel strategies for combating ovarian cancer drug resistance.
